Rising summer temperatures could spell hay fever misery for sufferers. Speaking at the Annual Nasaleze Press Event, Professor Jean Emberlin, Director of the National Pollen and Aerobiology Research Unit(1) said that “summer’s predicted rise in temperatures (2) is likely to cause pollen seasons to lengthen, resulting in a notably longer season of symptoms for hay fever sufferers.” Research published showed that the daily temperature extremes had risen by up to 4 °C over the last 50 years, and climate experts at the Met Office UK have predicted this will continue, which means prolonged symptoms for hay fever sufferers everywhere. Hay fever season could begin as early as March this year due to the cold snap this winter, as “a cold winter encourages birch trees to pollinate early,” according to Emberlin, who is a leading expert on pollen and hay fever. The two major types of pollen that cause allergic reactions are grass pollen and birch pollen. Birch pollen affects around 25% of hay fever sufferers and grass pollen affects 95% of hay fever sufferers.
These types of pollen affect sufferers at different times of the year, with birch pollen appearing in late March through to mid May, before grass pollen appears in late May or early June. Over the last three decades there has been a trend towards earlier starts for the birch pollen season at a rate of 5 days per decade with variations occurring from year to year. However the trends in weather towards warmer days in late summer and early autumn has meant that the grasses continue to flower for longer giving a longer pollen season.
The hay fever season presents extra problems for athletes that cannot intake cortisone nasal sprays as glucocorticosteroids are prohibited in-competition. NASALEZE is a natural nasal powder spray hayfever treatment that delivers fast, effective protection in minutes against hayfever as well as dust and pet allergies. NASALEZE stops the causes of allergy rather than just treating the symptoms, providing athletes with a drug free relief system to alieviate their hay fever symptoms.
Nasaleze is a natural inert cellulose powder which is applied to the nasal passage where it forms a gelatinous coating, thereby trapping aero-allergens and helping to prevent the initial allergic response. It can therefore be considered not only as an effective measure in helping to prevent the initial allergic reaction but also as a management strategy for reducing the symptoms of allergic rhinitis once triggered.
Professor Emberlin says: “Our research has found that Nasaleze quickly forms a gel which continues to expand slowly in the nasal cavities for up to 360 minutes after application. This means that it continues to be effective at blocking allergens. Our research also found that Nasaleze forms a very effective barrier to allergens with less than one per cent of allergen applied to the outside of the gel penetrating through in the first hour and only 14 per cent after three hours. These findings demonstrate how Nasaleze works and also that it does work very effectively.”
It works with the body’s own defence mechanisms to strengthen resistance to allergens. Studies show that by naturally enhancing nasal mucus, it’s possible to filter out allergens so that only clean air reaches the lungs. Nasaleze works by forming an invisible, gel like mucus lining in the nasal tract, which acts as a filter. Tests show in most hay fever cases, symptoms are controlled in minutes by using Nasaleze. Asthma cases are relieved in a few hours and even eczema has been known to subside after approximately three weeks of using twice daily. Contains no drugs and has no known side effects, it is 100% safe.
(1) University of Worcester
(2) Met Office UK
(3) Bernadette Diethart, Jean Emberlin*, Richard Lewis, Hydroxypropylmethylcellulose gel delays house dust mite allergen (Der p 1) diffusion in vitro, 2008.
We are fully committed at Nasaleze to a continuous clinical research programme to further prove the quality and efficacy of our products and to encourage those in the medical profession to recommend their patients to try it. We currently have eight studies on Nasaleze and a review paper by Professor Patrick J.D. Bouic of South Africa
Josling P, Steadman S. Use of cellulose powder for the treatment of seasonal allergic rhinitis Adv Ther. 2003 Jul-Aug;20(4):213-9. Open Clinical Trial.
Emberlin JC, Lewis RA. A double blind placebo controlled trial of inert cellulose powder for the relief of symptoms of Hay fever in adults. Curr Med Res Opin 2006;22(2)275-85.
Aivazis V, Bourli E, Maratou E et al. Study of Mucociliary Clearance and Peak Nasal Inspiratory Flow Rate in Children Before and After Therapy with Natural Cellulose Powder. U of Thessaloniki, Greece. Presented at World Allergy Congress in Munich, W Germany June 2005, also published in Nea Pediatrica Chronica, June 2005, Vol 5 no 2. Open Clinical Trial.
Emberlin JC, Lewis RA. A double blind, placebo controlled trial of inert cellulose powder for the relief of symptoms of hay fever in adults. Presented as a Poster at EAACI, Vienna June 2006.
Emberlin JC, Lewis RA. Double blind placebo controlled cross-over trial of Nasaleze by nasal provocation tests. Presented as a Poster EAACI, Gothenburg June 2007. Curr Med Res Opin; Vol 23; No 10; 2007, 2423-2431.
Vlahtis K. Clinical Study Results Summary. Presented at the Pan-Hellenic Conference of ENT Specialists on 19th March 2004 in Thessaloniki, Greece. Open Clinical Trial.
Preventing Airborne Infection With an Intranasal Cellulose Powder Formulation (Nasaleze Travel).
A dual-centered, randomized, blinded study so investigators could determine whether the level of airborne infection could be significantly reduced in patients randomly assigned to treatment with either Nasaleze cellulose extract alone or a combination of Nasaleze cellulose and powdered garlic extract (PGE). Professor R Hiltunen, PhD, PharmD University of Helsinki, Finland; PD Josling, BSc (Hons) Herbal Research Centre Battle, United Kingdom; MH James Nasaleze Limited, Isle of Man. Advances In Therapy Volume 24 No. 5 September/October 2007
Efficacy and safety of medical device Nasaval in prevention and treatment of persistent allergic rhinitis in adults and children (Nasaval is the brand name used in Russia for Nasaleze).
This paper describes the findings of an open non-comparative clinical study of efficacy and safety of an ultra-disperse cellulose preparation in prevention and treatment of persistent allergic rhinitis (AR). Zakharzhevskaya TV, Sidorenko IV, Treskunov VK, Karaulov AV Sechenov Medical Academy, Moscow. This was presented at Moscow XVI Congress for Men and drug April 06-10, 2009
A Review of the Efficacy and Safety of Nasaleze in the Prevention and Management of Allergic Rhinitis.
A review paper by Professor Patrick JD Bouic, Division of Medical Microbiology, Dept of Pathology, University of Stellenbosch, South Africa. Nasaleze has been on sale since 1994 in the UK, however this review paper was necessitated by the fact that the product was unknown at the time of its launch in South Africa. Published in The Open Allergy Journal, 2008, 1, 1-4.
Registered as a Class 1 Medical Device under EU Directive 93/42/EEC.
Please visit www.nasaleze.com for more information.